This study is being conducted to evaluate the effectiveness and safety of LAMICTAL added to the current therapy of pediatric patients age 1-24 months old with partial seizures. The medication used in this study has been approved by FDA for the adjunctive treatment of partial seizures in patients 2 years and older.

INCLUSION CRITERIA:

• Have a confident diagnosis of epilepsy
• Must be experiencing 4 or more reliably detectable partial seizures per month while receiving at least 1 anti-epileptic drug (AED)
• Must weigh at least 7 lbs if currently receiving enzyme inducing antiepileptic drugs (EIADs) OR weigh at least 15 lbs if currently receiving non-enzyme inducing antiepileptic drugs (non-EIADs)
• Have no underlying chronic metabolism problems
• Have normal lab results
• Have a normal electrocardiogram (ECG)

EXCLUSION CRITERIA:

• Have a diagnosis of severe, progressive myoclonus.
• Have seizures not related to epilepsy.
• Have previously demonstrated sensitivity or allergic reaction to the study drug or its related compounds.
• Have progressive or unstable condition of the nervous system.
• Used experimental medication within 30 of enrollment into the study.
• Have any significant, chronic heart, kidney, liver or stomach/intestinal (GI) condition.
• Current use of the medication felbamate.
• Current use of adrenocorticotrophic hormone (ACTH).
• Following a ketogenic diet.
• Receiving vagal nerve stimulation (VNS).

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.